https://doi.org/ 10.33472/AFJBS.6.9.2024.1171-1196

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

PHARMACOGENOMICS STUDIES OF TRADITIONAL MEDICINE: EXPLORING THE GENETIC BASIS OF PLANT THERAPEUTICS

Mahaveer Singh [1], Saniya [2], Rupa Sengupta [3], Trishna Das [4], Dhaneshwar kumar vishwakarma [5], Deepika Aggarwal [6], Krishna Chandra Panda [7], Smriti Rekha Chanda Das [8]*

1. Associate professor, DR Karigowda College of Pharmacy, Hassan
2. Research scholar, Jamia Hamdard University, Mehrauli - Badarpur Rd, near Batra Hospital, Block D, Hamdard Nagar, New Delhi, Delhi 110062
3. Assistant professor, School of pharmaceutical Sciences, Girijananda Chowdhury University,Azara, Guwahati,Assam,781014.
4. Associate professor, School of Pharmaceutical Sciences, Guwahati, Girijananda Chowdhury University, Assam Azara, PIN 781017
5. Associate professor, Kailash Institute of Pharmacy and Management, Gida Gorakhpur
6. Principal, Bharat Institute of Pharmacy, Pehladpur, Babain, Kurukshetra - 136156
7. Associate Professor, Roland Institute of Pharmaceutical Sciences, Berhampur, Khodasingi,Pin-760010
8. Associate Professor, School of Pharmaceutical Science, Girijananda Chowdhury University, Azara, Guwahati, Assam, 781017

Corresponding Author: Dr. Smriti Rekha Chanda Das

Designation and Affiliation: Associate Professor, School of Pharmaceutical Science, Girijananda Chowdhury University, Azara, Guwahati, Assam, 781017

Email Id: smriti_pharmag@gcuniversity.ac.in

Article History
Volume 6,Issue 9, 2024
Received: 26-03-2024
Accepted : 28-04-2024
doi: 10.33472/AFJBS.6.9.2024.1171-1196

Abstract:
The integration of pharmacogenomics into traditional medicine presents a paradigm shift in healthcare, offering personalized treatment approaches while respecting cultural diversity and promoting social equity. This review synthesizes the current understanding of pharmacogenomics studies in traditional medicine, exploring the genetic basis of plant therapeutics and elucidating the ethical, legal, and social implications (ELSI) associated with this integration.Historically, traditional medicine has been deeply rooted in cultural diversity, encompassing diverse healing practices such as Ayurveda, Traditional Chinese Medicine (TCM), and Indigenous healing traditions. Pharmacogenomic studies have shed light on the genetic diversity of medicinal plants, revealing the intricate interplay between genetic variations and therapeutic efficacy. Case studies have demonstrated the influence of genetic variations on the production of bioactive compounds and the pharmacological activities of medicinal plants, highlighting the importance of genetic diversity in optimizing therapeutic outcomes.Methodologies employed in pharmacogenomic studies of traditional medicine include genomic sequencing, genome-wide association studies (GWAS), gene expression profiling, metabolomic analysis, and pharmacogenomic modeling. These methodologies enable researchers to unravel the genetic basis of drug response variability, identify predictive biomarkers, and optimize treatment strategies tailored to individual genetic profiles.However, the integration of pharmacogenomics into traditional medicine raises complex ELSI considerations that must be carefully addressed. Ethical considerations include informed consent, community engagement, benefit sharing, and cultural preservation. Legal frameworks governing the use of genetic information, intellectual property rights, and indigenous rights play a crucial role in shaping research conduct and ensuring equitable access to benefits. Social implications encompass cultural revitalization, health equity, interdisciplinary collaboration, and education and awareness efforts.To navigate these challenges, stakeholders must engage in transparent dialogue, foster partnerships with indigenous and local communities, and advocate for inclusive policies and practices. By embracing a holistic approach that values cultural sensitivity, ethical integrity, and social justice, we can harness the transformative potential of pharmacogenomics to advance personalized traditional medicine and improve health outcomes for all.

Keywords: pharmacogenomics, traditional medicine, genetic basis, ethical considerations, legal frameworks, social implications

I. Introduction

Pharmacogenomics, a burgeoning field within the broader realm of pharmacology and genomics, focuses on the study of how an individual's genetic makeup influences their response to drugs. It examines how genetic variations can impact drug metabolism, efficacy, and adverse reactions[1]. This interdisciplinary field integrates principles from genetics, genomics, pharmacology, and bioinformatics to elucidate the genetic basis of drug response variability among individuals[2]. By understanding the genetic factors underlying drug response, pharmacogenomics aims to facilitate personalized medicine approaches, where treatments can be tailored to an individual's genetic profile to optimize therapeutic outcomes while minimizing adverse effects[3].Traditional medicine encompasses a diverse range of healing practices, approaches, and therapies that have been developed over centuries within various cultures and societies worldwide. It includes systems such as Ayurveda, Traditional Chinese Medicine (TCM), Indigenous healing practices, and numerous other folk medicine traditions[4]. Traditional medicine plays a crucial role in global healthcare, particularly in regions where it is the primary form of healthcare available or where cultural beliefs and practices strongly influence healthcare decisions. In many parts of the world, traditional medicine coexists alongside modern Western medicine, offering complementary and

alternative approaches to health and wellness[5].Plants have long been a source of medicinal compounds used in traditional healing practices. Many pharmaceutical drugs have been derived from or inspired by natural compounds found in plants. Understanding the genetic basis of plant therapeutics is essential for several reasons[6]. Firstly, it can provide insights into the mechanisms of action of medicinal plants, helping to elucidate how specific plant compounds interact with biological targets in the body to produce therapeutic effects[7]. Secondly, genetic studies can shed light on the variability in response to plant-based treatments among individuals, including differences in efficacy and adverse reactions. Thirdly, knowledge of plant genetics can inform strategies for sustainable cultivation, conservation, and breeding of medicinal plants, ensuring a stable supply of therapeutic compounds for future generations[8].The primary objective of this review is to consolidate and analyze current research in the field of pharmacogenomics as it pertains to traditional medicine. By synthesizing existing pharmacogenomics studies focused on plant therapeutics, this review aims to provide a comprehensive overview of the genetic basis of traditional medicine practices. Specifically, it seeks to examine how genetic variations in both individuals and medicinal plants influence drug response and efficacy in the context of traditional healing modalities[9]. Through this synthesis, the review aims to identify patterns, trends, and gaps in the literature, thereby contributing to a deeper understanding of the interplay between genetics, traditional medicine, and personalized healthcare. Ultimately, the review seeks to highlight the potential of pharmacogenomics to enhance the efficacy, safety, and accessibility of traditional medicine practices in diverse cultural and geographical contexts.



Figure 1: overview of Pharmacogenomics

II. Historical Perspective on Traditional Medicine

A. Evolution of Traditional Medicine Practices

Traditional medicine has a rich and complex history that spans thousands of years, evolving in response to cultural, social, and environmental influences. The origins of traditional healing practices can be traced back to ancient civilizations where early humans relied on natural remedies and rituals to address health concerns[10]. Over time, these primitive healing methods evolved into more structured systems of medicine as knowledge was passed down through generations and refined through observation and experimentation.The

evolution of traditional medicine practices was often intertwined with the development of human civilization[11]. In ancient societies such as those of Mesopotamia, Egypt, Greece, China, and India, healing traditions emerged and evolved in parallel with advancements in agriculture, trade, and urbanization. These early civilizations developed sophisticated medical systems based on empirical knowledge, spiritual beliefs, and philosophical principles[12].The spread of ideas, trade routes, and conquests facilitated the exchange of medical knowledge between different cultures, leading to the cross-pollination of healing practices. For example, the Silk Road played a pivotal role in the transmission of medical knowledge between East and West, fostering the exchange of ideas and practices between ancient China, India, the Middle East, and Europe[13].Throughout history, traditional medicine practices continued to evolve in response to changing social, political, and environmental contexts. In some cases, traditional healing methods were suppressed or marginalized by dominant medical paradigms, while in others, they persisted and adapted to new circumstances[14]. Despite periods of decline and resurgence, traditional medicine has remained a vital component of healthcare systems worldwide, reflecting the enduring human quest for health and well-being.

B. Cultural Diversity and the Use of Plant-Based Remedies

One of the defining characteristics of traditional medicine is its cultural diversity, with each culture and community developing its own unique healing practices based on local knowledge, beliefs, and resources. Plant-based remedies have been central to traditional healing systems for millennia, with medicinal plants serving as a primary source of therapeutic compounds[15].The use of plant-based remedies is rooted in the deep connection between humans and the natural world, where plants have been revered for their healing properties since ancient times. Indigenous cultures around the globe have developed intricate systems of plant knowledge, passed down through oral traditions, ceremonies, and healing rituals[16].Cultural beliefs and practices often influence the selection, preparation, and administration of plant-based remedies. In many traditional healing systems, plants are viewed not only as sources of physical healing but also as conduits for spiritual healing, connecting individuals to the natural world and ancestral wisdom[17].The diversity of plant-based remedies reflects the vast array of ecosystems and botanical resources found across different regions and climates. From the rainforests of the Amazon to the deserts of Africa, indigenous peoples have developed unique pharmacopoeias based on the plants that grow in their local environments[18]. Traditional healers, known by various names such as shamans, herbalists, or medicine men, possess intimate knowledge of local plants and their medicinal properties, which they use to diagnose and treat illness[19].The use of plant-based remedies extends beyond indigenous cultures to include traditional medicine systems such as Ayurveda, Traditional Chinese Medicine (TCM), Unani, and Western herbalism. These systems have their own philosophies, diagnostic methods, and treatment modalities, but they share a common reliance on plants as a primary source of medicine[20].

C. Examples of Traditional Medicine Systems (e.g., Ayurveda, Traditional Chinese Medicine, Indigenous Healing Practices)

Traditional medicine encompasses a diverse array of healing systems practiced by cultures around the world. These systems vary in their philosophical foundations, diagnostic approaches, and therapeutic modalities, but they share a common emphasis on holistic healing and the interconnectedness of body, mind, and spirit. Some prominent examples of

traditional medicine systems include:
1. Ayurveda: Originating in ancient India over 5,000 years ago, Ayurveda is one of the world's oldest holistic healing systems. It is based on the concept of maintaining balance among the body's three doshas (Vata, Pitta, and Kapha) and employs a combination of herbal remedies, dietary modifications, yoga, meditation, and lifestyle practices to promote health and prevent disease[21].

2. Traditional Chinese Medicine (TCM): TCM is a comprehensive system of medicine that has been practiced in China for over 2,000 years. It is based on the principles of Yin and Yang and the Five Elements theory, which describe the dynamic balance of opposing forces in the body. TCM utilizes acupuncture, herbal medicine, dietary therapy, massage (Tui Na), and qigong to restore harmony and balance to the body's energy systems[22].

3. Indigenous Healing Practices: Indigenous peoples around the world have developed their own unique healing traditions based on their cultural beliefs, spiritual practices, and relationships with the natural world[23]. These practices often involve the use of medicinal plants, ceremonies, rituals, and storytelling to address physical, emotional, and spiritual ailments. Examples include Native American healing traditions, Aboriginal healing practices in Australia, and traditional healing practices among indigenous communities in Africa, Asia, and Latin America[24].

III. Pharmacogenomics: Concepts and Applications

A. Scope of Pharmacogenomics

Pharmacogenomics is a rapidly evolving field that combines principles from pharmacology and genomics to understand how an individual's genetic makeup influences their response to drugs. At its core, pharmacogenomics seeks to elucidate the genetic factors that contribute to variability in drug response among individuals. This includes studying how genetic variations can affect drug metabolism, efficacy, toxicity, and adverse reactions[25].The scope of pharmacogenomics extends beyond the study of individual genes to encompass broader genomic factors such as gene-gene interactions, gene-environment interactions, and epigenetic modifications. By integrating genomic data with clinical information, pharmacogenomics aims to personalize medicine by tailoring drug treatments to individual patients based on their genetic profiles. This approach holds the promise of optimizing therapeutic outcomes while minimizing the risk of adverse reactions[26].Pharmacogenomics has applications across various fields of medicine, including oncology, cardiology, psychiatry, infectious diseases, and beyond. It has the potential to revolutionize drug development, clinical practice, and healthcare delivery by enabling more precise and targeted approaches to treatment[27].

B. Role of Genetics in Drug Response Variability

Genetic factors play a crucial role in determining an individual's response to drugs. Genetic variations can influence drug absorption, distribution, metabolism, and excretion, collectively known as pharmacokinetic processes, as well as drug-target interactions and downstream biological responses, known as pharmacodynamic processes[28].One of the most well-

studied examples of genetic variability in drug response is in the cytochrome P450 (CYP) family of enzymes, which are responsible for metabolizing a wide range of drugs. Genetic polymorphisms in CYP genes can result in altered enzyme activity, leading to differences in drug metabolism and clearance rates among individuals. These variations can impact drug efficacy and toxicity, potentially affecting treatment outcomes and patient safety[29].In addition to pharmacokinetic factors, genetic variations can also influence drug response through pharmacodynamic mechanisms. This includes variations in drug targets, such as receptors or enzymes, which can affect the sensitivity or responsiveness of an individual to a particular drug. Genetic variations in drug transporters, drug-metabolizing enzymes, drug receptors, and other pharmacologically relevant genes all contribute to interindividual variability in drug response[30].Understanding the genetic basis of drug response variability is essential for developing personalized treatment strategies that maximize therapeutic efficacy while minimizing adverse effects. Pharmacogenomic testing, which involves analyzing an individual's genetic profile to predict their response to specific drugs, holds great promise for guiding drug selection, dosing, and monitoring in clinical practice[31].

C. Pharmacogenomic Approaches for Studying Traditional Medicine

Pharmacogenomic approaches can also be applied to the study of traditional medicine, particularly in the context of plant-based therapeutics. Traditional medicine systems, such as Ayurveda, Traditional Chinese Medicine (TCM), and Indigenous healing practices, often rely on complex mixtures of herbal remedies that contain multiple bioactive compounds with varying pharmacological effects[32].Pharmacogenomic studies of traditional medicine seek to elucidate the genetic basis of individual variability in response to plant-based remedies. This involves integrating genomic data with clinical information to identify genetic factors that influence the absorption, metabolism, and efficacy of medicinal plants. By understanding how genetic variations impact the pharmacokinetics and pharmacodynamics of plant-based remedies, researchers can identify biomarkers that predict individual responses to specific herbal preparations[33].Pharmacogenomic approaches for studying traditional medicine may include genome-wide association studies (GWAS), which aim to identify genetic variants associated with drug response phenotypes, as well as candidate gene studies focused on specific genes involved in drug metabolism, transport, or target interactions. Additionally, transcriptomic, metabolomic, and epigenomic analyses can provide insights into the molecular mechanisms underlying the therapeutic effects of medicinal plants and how they interact with the human genome[34].By integrating pharmacogenomic data with traditional knowledge systems, researchers can gain a deeper understanding of the mechanisms of action of medicinal plants and optimize their use in personalized healthcare. This interdisciplinary approach has the potential to bridge the gap between traditional and modern medicine, facilitating the integration of evidence-based practices into healthcare systems worldwide[35].

D. Challenges and Limitations in Pharmacogenomic Research

While pharmacogenomics holds great promise for advancing personalized medicine, several challenges and limitations must be addressed to realize its full potential. One major challenge is the complexity of the human genome, which contains millions of genetic variants that can

influence drug response. Identifying clinically relevant variants and understanding their functional significance requires large-scale genomic studies and sophisticated bioinformatics analyses[36].Another challenge is the heterogeneity of drug response phenotypes, which can be influenced by multiple genetic, environmental, and clinical factors. Accounting for this heterogeneity requires robust study designs, well-defined phenotypes, and comprehensive data collection strategies. Additionally, population diversity must be taken into account to ensure that pharmacogenomic findings are applicable across different ethnic and racial groups[37].

IV. Genetic Basis of Plant Therapeutics

A. Plant-Derived Therapeutic Compounds

Plants have been a vital source of therapeutic compounds for centuries, serving as the foundation of traditional healing practices worldwide. The rich biodiversity of plant species has yielded a diverse array of bioactive molecules with medicinal properties, many of which have been used to treat a wide range of health conditions[38].Plant-derived therapeutic compounds encompass a broad spectrum of chemical classes, including alkaloids, flavonoids, terpenoids, phenolics, and polysaccharides, among others. These compounds exhibit various pharmacological activities, such as anti-inflammatory, antimicrobial, antioxidant, analgesic, and anticancer effects, making them valuable resources for drug discovery and development[39].Many modern pharmaceutical drugs are derived from or inspired by natural compounds found in plants. For example, the anti-malarial drug quinine is derived from the bark of the cinchona tree, while the pain reliever morphine is derived from the opium poppy. Other examples include aspirin (from willow bark), digitalis (from foxglove), and taxol (from the Pacific yew tree)[40].Advances in phytochemistry, bioinformatics, and synthetic biology have facilitated the identification, isolation, and characterization of bioactive compounds from medicinal plants. These compounds serve as lead molecules for the development of new drugs and provide insights into the mechanisms of action of traditional herbal remedies[41].

B. Genetic Diversity of Medicinal Plants

Genetic diversity is a fundamental aspect of medicinal plants, contributing to their ability to produce a wide range of bioactive compounds with diverse pharmacological activities. Genetic variation within and among plant populations is influenced by factors such as geographic distribution, environmental conditions, reproductive strategies, and evolutionary history[42].Medicinal plants exhibit genetic diversity at multiple levels, including within-species variation, between-species variation, and population-level variation. This genetic diversity provides the raw material for natural selection and adaptation, allowing plants to respond to changing environmental pressures and threats from pathogens and predators[43].Understanding the genetic diversity of medicinal plants is essential for conservation, breeding, and sustainable utilization efforts. Conservation genetics seeks to assess and preserve the genetic diversity of endangered or threatened plant species to ensure their long-term survival. Breeding programs aim to develop improved cultivars with desirable traits, such as higher yields, enhanced resistance to pests and diseases, and increased production of bioactive compounds[44].Genomic technologies, such as next-generation sequencing (NGS), genotyping-by-sequencing (GBS), and genome-wide association studies

(GWAS), have revolutionized our ability to study the genetic diversity of medicinal plants. These tools enable researchers to analyze large-scale genomic data and identify genetic markers associated with important traits, such as drug content, potency, and quality[45].

Table 1: Ethical, Legal, and Social Implications (ELSI) of Pharmacogenomics in Traditional Medicine: Considerations and Strategies

ELSI Aspect	Considerations	Strategies	References
Informed Consent	Cultural sensitivity, language barriers, comprehension	Develop culturally tailored consent forms and educational materials; Provide interpreter services and community outreach	[2]
Community Engagement	Indigenous rights, community autonomy, benefit-sharing	Establish community advisory boards; Prioritize community involvement in research design and decision-making	[7]
Privacy and Confidentiality	Genetic data protection, confidentiality, data security	Implement robust data encryption and anonymization protocols; Adhere to data privacy regulations and guidelines	[10]
Benefit Sharing	Equitable compensation, resource allocation, transparency	Negotiate benefit-sharing agreements with community stakeholders; Establish mechanisms for fair resource distribution	[12]
Intellectual Property Rights	Ownership, licensing, commercialization, indigenous rights	Ensure indigenous peoples' rights to control and benefit from genetic discoveries; Foster collaboration and knowledge exchange	[16]
Education and Awareness	Genetics literacy, cultural competency, advocacy	Provide education and training on ELSI issues; Conduct public awareness campaigns and stakeholder consultations	[19]
Policy Reform	Legal frameworks, regulatory oversight, policy advocacy	Advocate for policy reforms that address ELSI concerns; Engage with policymakers and regulatory authorities	[15]

C. Identification of Pharmacologically Active Compounds

The identification of pharmacologically active compounds from medicinal plants is a multifaceted process that involves a combination of phytochemical, pharmacological, and bioinformatics approaches. Phytochemical screening techniques, such as chromatography,

spectroscopy, and mass spectrometry, are used to isolate and characterize bioactive compounds from plant extracts[46].Pharmacological assays are employed to evaluate the biological activities of isolated compounds, including their effects on cell viability, enzyme inhibition, receptor binding, and other relevant endpoints. High-throughput screening (HTS) platforms enable the rapid screening of large compound libraries against specific drug targets or disease models, accelerating the drug discovery process[47].Bioinformatics tools and databases play a critical role in the identification and characterization of pharmacologically active compounds from medicinal plants. Computational methods, such as virtual screening, molecular docking, and molecular dynamics simulations, are used to predict the binding affinity and interactions of bioactive compounds with target proteins[48].Metabolomics and transcriptomics approaches provide insights into the metabolic pathways and gene expression profiles associated with the biosynthesis of bioactive compounds in medicinal plants. By integrating multi-omics data, researchers can gain a comprehensive understanding of the genetic and biochemical mechanisms underlying the therapeutic properties of medicinal plants[49].

D. Influence of Genetic Variations on Plant Therapeutic Efficacy

Genetic variations within medicinal plant species can influence the composition, concentration, and bioactivity of bioactive compounds, ultimately impacting their therapeutic efficacy and safety. Genetic factors that influence the production of bioactive compounds include genes involved in biosynthetic pathways, transcriptional regulators, and environmental response mechanisms[50].Single nucleotide polymorphisms (SNPs), insertions/deletions (indels), and copy number variations (CNVs) in genes encoding enzymes involved in secondary metabolism can affect the catalytic activity and substrate specificity of these enzymes, leading to variations in the production of bioactive compounds[51]. For example, polymorphisms in genes encoding key enzymes in the biosynthesis of alkaloids, terpenoids, and flavonoids have been associated with differences in drug content and potency in medicinal plants.Environmental factors, such as light, temperature, water availability, soil nutrients, and biotic interactions, can also influence the expression of genes involved in secondary metabolism and the accumulation of bioactive compounds in medicinal plants[52]. Genotype-by-environment interactions (GxE) play a significant role in shaping the chemical composition and therapeutic properties of plant populations across different ecological niches.Understanding the genetic basis of variation in therapeutic efficacy among plant populations is essential for optimizing cultivation practices, selecting superior germplasm for breeding programs, and ensuring the consistency and quality of herbal medicines[53]. Integrating genetic and environmental data can help identify genetic markers associated with desirable traits and develop predictive models for optimizing plant production and utilization.

E. Case Studies Demonstrating the Genetic Basis of Plant Therapeutics

Several case studies have demonstrated the influence of genetic variations on the therapeutic properties of medicinal plants. For example, studies in Artemisia annua, the source of the anti-malarial compound artemisinin, have identified genetic loci associated with artemisinin content and yield, providing insights into the genetic basis of variation in drug potency among plant populations[54].Similarly, genetic studies in Panax ginseng, a popular traditional

herbal remedy, have revealed genetic markers associated with ginsenoside content, pharmacological activities, and agronomic traits, facilitating the breeding of high-yielding cultivars with enhanced therapeutic properties[55].In Cannabis sativa, genetic studies have identified genes involved in the biosynthesis of cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), and their precursors. These findings have implications for the breeding of cannabis varieties with specific cannabinoid profiles tailored for medical or recreational use[56].Other case studies have focused on medicinal plants used in traditional healing practices, such as Ayurveda and Traditional Chinese Medicine (TCM). Genetic studies in Withania somnifera, known as ashwagandha in Ayurveda, have identified genes involved in the biosynthesis of bioactive compounds, such as withanolides, and their regulation by environmental factors[57].Similarly, genetic studies in Panax notoginseng, a widely used medicinal herb in TCM, have elucidated the genetic basis of variation in ginsenoside content, pharmacological activities, and disease resistance. These studies highlight the importance of genetic diversity and environmental factors in shaping the therapeutic properties of medicinal plants and provide valuable insights for their conservation, cultivation, and utilization in healthcare[58].

V. Pharmacogenomics Studies in Traditional Medicine

A. Methodologies Used in Pharmacogenomic Studies of Traditional Medicine

Pharmacogenomic studies of traditional medicine involve the application of various methodologies to elucidate the genetic basis of drug response variability and optimize therapeutic outcomes. These methodologies encompass a range of experimental and computational approaches tailored to the unique characteristics of traditional medicine systems and their plant-based therapeutics[59].

1. Genomic Sequencing: Whole-genome sequencing (WGS) and targeted sequencing techniques, such as amplicon sequencing or exome sequencing, are used to analyze the genetic makeup of individuals and medicinal plants. Genomic sequencing allows researchers to identify genetic variants associated with drug response phenotypes and predict individual responses to specific herbal remedies[60].

2. Genome-Wide Association Studies (GWAS): GWAS involve scanning the genomes of large cohorts of individuals to identify genetic variants associated with specific traits or phenotypes, such as drug efficacy or toxicity. In the context of traditional medicine, GWAS can identify genetic markers associated with variation in response to herbal treatments and provide insights into the underlying mechanisms[61].

3. Gene Expression Profiling: Transcriptomic studies, such as RNA sequencing (RNA-seq) or microarray analysis, are used to measure gene expression levels in response to herbal treatments. Gene expression profiling can identify genes and pathways that are differentially regulated in individuals with varying drug responses, helping to elucidate the molecular mechanisms of action of medicinal plants[62].

4. Metabolomic Analysis: Metabolomics involves the comprehensive analysis of small-

molecule metabolites present in biological samples, such as blood, urine, or plant extracts. Metabolomic studies can identify biomarkers of drug response and characterize the metabolic pathways affected by herbal treatments, providing insights into their therapeutic effects and mechanisms of action[63].

5. Pharmacogenomic Modeling: Computational modeling approaches, such as pharmacokinetic-pharmacodynamic (PK-PD) modeling or machine learning algorithms, are used to integrate genomic, pharmacokinetic, and pharmacodynamic data to predict individual responses to herbal remedies. Pharmacogenomic modeling can facilitate personalized treatment optimization and guide clinical decision-making in traditional medicine practice[22].

6. Ethnopharmacology and Traditional Knowledge Systems: Ethnopharmacological studies involve the systematic documentation and analysis of traditional knowledge systems related to medicinal plants and their therapeutic uses. Ethnopharmacological data can inform pharmacogenomic studies by guiding the selection of candidate genes, pharmacologically active compounds, and herbal formulations for investigation[64].

7. Multi-Omics Integration: Integrating data from multiple omics platforms, such as genomics, transcriptomics, metabolomics, and proteomics, enables a comprehensive understanding of the genetic and molecular basis of drug response variability in traditional medicine. Multi-omics integration can reveal complex interactions between genetic variations, gene expression patterns, and metabolic pathways, shedding light on the holistic mechanisms of action of herbal remedies[3,7,65].

B. Key Findings and Insights from Pharmacogenomic Research

Pharmacogenomic research in traditional medicine has yielded valuable insights into the genetic basis of drug response variability and the mechanisms of action of herbal remedies. Some key findings and insights include:

1. Identification of Genetic Markers: Pharmacogenomic studies have identified genetic variants associated with variation in drug response phenotypes, such as drug efficacy, toxicity, and adverse reactions. These genetic markers can serve as predictive biomarkers for personalized treatment optimization and clinical decision-making[66].

2. Characterization of Pharmacogenes: Studies have characterized genes involved in drug metabolism, transport, and target interactions, elucidating their role in mediating individual responses to herbal treatments. Pharmacogenomic studies have identified polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, and drug targets that influence the pharmacokinetics and pharmacodynamics of herbal remedies[24,25].

3. Elucidation of Molecular Pathways: Pharmacogenomic research has elucidated the molecular pathways underlying the therapeutic effects of medicinal plants and their interactions with the human genome. Studies have revealed the involvement of various

signaling pathways, metabolic pathways, and cellular processes in mediating the pharmacological activities of herbal remedies[67].

4. Validation of Traditional Knowledge: Pharmacogenomic studies have provided scientific validation for traditional knowledge systems related to medicinal plants and their therapeutic uses. By linking genetic variations to traditional healing practices, pharmacogenomic research has helped bridge the gap between traditional medicine and modern science, fostering mutual respect and collaboration between different healthcare paradigms[68].

5. Development of Personalized Treatment Strategies: Insights from pharmacogenomic research have enabled the development of personalized treatment strategies tailored to individual genetic profiles. By integrating genomic data with clinical information, pharmacogenomic testing can guide drug selection, dosing, and monitoring in traditional medicine practice, optimizing therapeutic outcomes and minimizing the risk of adverse reactions[15,7,69].

C. Impact of Genetic Variations on Traditional Medicine Efficacy and Safety

Genetic variations play a significant role in determining individual responses to traditional medicine treatments, influencing both efficacy and safety outcomes. The impact of genetic variations on traditional medicine efficacy and safety can be understood through several key mechanisms:

1. Drug Metabolism: Genetic polymorphisms in genes encoding drug-metabolizing enzymes, such as cytochrome P450 (CYP) enzymes, can affect the rate and extent of drug metabolism, leading to differences in drug efficacy and toxicity[17]. Variants in pharmacogenes involved in phase I and phase II metabolism pathways can influence the bioavailability and clearance of active compounds in herbal remedies, altering their therapeutic effects[70].

2. Drug Transport: Genetic variations in genes encoding drug transporters, such as ATP-binding cassette (ABC) transporters and solute carrier (SLC) transporters, can impact the absorption, distribution, and elimination of herbal remedies. Polymorphisms in drug transporter genes can affect the cellular uptake and efflux of bioactive compounds, altering their pharmacokinetic profiles and therapeutic concentrations[19].

3. Drug Targets: Genetic variations in genes encoding drug targets, such as receptors, enzymes, and signaling proteins, can influence the sensitivity, specificity, and responsiveness of individuals to herbal treatments. Polymorphisms in drug target genes can affect the binding affinity, downstream signaling pathways, and physiological responses elicited by pharmacologically active compounds in medicinal plants[71].

4. Adverse Drug Reactions: Genetic predisposition to adverse drug reactions (ADRs) can result from inherited variations in genes involved in drug metabolism, transport, and target interactions. Pharmacogenomic studies have identified genetic markers associated with increased susceptibility to ADRs, enabling the identification of at-risk individuals and the

implementation of personalized risk mitigation strategies[31,2].

5. Population Diversity: Genetic variations in pharmacogenes can exhibit population-specific patterns, leading to differences in drug response phenotypes among ethnic and racial groups. Population-based pharmacogenomic studies have revealed interethnic differences in allele frequencies, genotype-phenotype associations, and drug response outcomes, highlighting the importance of considering population diversity in personalized medicine approaches[72].

D. Future Directions and Potential Applications of Pharmacogenomics in Traditional Medicine

The future of pharmacogenomics in traditional medicine holds immense promise for advancing personalized healthcare and optimizing the use of plant-based therapeutics. Several key directions and potential applications include:

1. Precision Medicine: Pharmacogenomics enables the practice of precision medicine by tailoring treatment strategies to individual genetic profiles. In the context of traditional medicine, pharmacogenomic testing can guide the selection, dosing, and monitoring of herbal remedies based on patients' genetic variants, optimizing therapeutic outcomes and minimizing the risk of adverse reactions[73].

2. Drug Discovery and Development: Pharmacogenomic studies provide insights into the genetic basis of drug response variability, facilitating the discovery and development of new plant-based therapeutics[6]. By elucidating the molecular mechanisms of action of medicinal plants and their interactions with the human genome, pharmacogenomics can inform rational drug design and optimization efforts, leading to the discovery of novel bioactive compounds with enhanced efficacy and safety profiles[39].

3. Herbal Quality Control: Pharmacogenomic approaches can be used to assess the quality, authenticity, and consistency of herbal medicines through genetic fingerprinting and molecular profiling techniques. By analyzing the genetic makeup of medicinal plants and their derived products, pharmacogenomics can help identify adulterants, contaminants, and variations in chemical composition, ensuring the safety and efficacy of herbal remedies[74].

4. Ethnopharmacological Research: Pharmacogenomics can complement ethnopharmacological research by providing scientific validation for traditional knowledge systems related to medicinal plants and their therapeutic uses. By integrating genomic data with traditional healing practices, pharmacogenomic studies can bridge the gap between traditional medicine and modern science, fostering mutual respect and collaboration between different healthcare paradigms[22,7].

5. Global Health Equity: Pharmacogenomics has the potential to promote global health equity by enabling personalized healthcare approaches that are tailored to the specific needs and genetic backgrounds of diverse populations. By addressing interethnic differences in drug response phenotypes and optimizing treatment strategies for underrepresented populations,

pharmacogenomics can help reduce healthcare disparities and improve access to personalized medicine worldwide[75].

VI. Ethical, Legal, and Social Implications (ELSI)

A. Ethical Considerations in Pharmacogenomics Research Involving Traditional Medicine

Pharmacogenomics research involving traditional medicine raises several ethical considerations that must be carefully addressed to ensure the responsible conduct of research and protect the rights and welfare of individuals and communities involved. Some key ethical considerations include:

1. Informed Consent: Informed consent is essential in pharmacogenomics research to ensure that participants understand the purpose, risks, benefits, and implications of the study. In the context of traditional medicine, where cultural beliefs and practices may influence healthcare decision-making, researchers must obtain culturally sensitive informed consent that respects participants' autonomy and values[38].

2. Community Engagement: Traditional medicine research often involves indigenous and local communities with unique cultural, social, and spiritual beliefs. Researchers should engage with these communities in a culturally appropriate and respectful manner, involving community members in all stages of the research process, from study design to dissemination of results[76].

3. Respect for Cultural Practices: Traditional medicine practices are deeply rooted in cultural traditions, rituals, and knowledge systems that may differ from Western biomedical perspectives. Researchers must respect and preserve the cultural integrity of traditional healing practices, avoiding exploitation, appropriation, or misrepresentation of indigenous knowledge and resources[22].

4. Benefit Sharing: Pharmacogenomics research involving traditional medicine should prioritize the equitable distribution of benefits and resources, ensuring that communities that contribute to research efforts receive fair compensation, recognition, and access to resulting innovations. Benefit-sharing agreements should be negotiated in collaboration with community stakeholders to promote transparency and accountability[77].

5. Privacy and Confidentiality: Protecting the privacy and confidentiality of research participants is paramount in pharmacogenomics research, where genetic information is sensitive and potentially stigmatizing. Researchers should implement robust data security measures and anonymization protocols to safeguard the confidentiality of genetic data and minimize the risk of unauthorized access or disclosure[19].

6. Risk-Benefit Assessment: Pharmacogenomics research may pose risks to participants, such as privacy breaches, psychological distress, or unintended consequences of genetic testing. Researchers should conduct thorough risk-benefit assessments to weigh the potential harms

and benefits of the research and implement appropriate safeguards to mitigate risks and maximize benefits[78].

7. Scientific Integrity: Upholding scientific integrity and research ethics is essential in pharmacogenomics research to maintain public trust and credibility. Researchers should adhere to rigorous methodological standards, transparent reporting practices, and ethical guidelines established by regulatory authorities and professional organizations[79].

B. Legal Frameworks Governing the Use of Genetic Information in Traditional Medicine

The use of genetic information in traditional medicine is subject to various legal frameworks and regulations that govern the collection, storage, use, and disclosure of genetic data. These legal frameworks aim to protect individuals' privacy, autonomy, and rights while promoting scientific research and innovation[33]. Some key legal considerations include:

1. Data Protection and Privacy Laws: Many countries have enacted data protection and privacy laws that regulate the collection, processing, and storage of genetic information. These laws typically require informed consent for the collection and use of genetic data, specify data security requirements, and establish rights for individuals to access, correct, and control their genetic information.

2. Healthcare Regulations: Healthcare regulations may govern the use of genetic testing and personalized medicine approaches in clinical practice. These regulations may require genetic tests to be performed by licensed healthcare professionals, ensure the accuracy and reliability of genetic tests, and mandate informed consent and genetic counseling for patients undergoing testing[80].

3. Intellectual Property Rights: Intellectual property laws may govern the ownership, licensing, and commercialization of genetic discoveries and innovations in traditional medicine. Researchers and companies may seek patents for novel genetic sequences, biomarkers, or therapeutic targets identified through pharmacogenomics research, which can impact access to and affordability of genetic testing and treatments[29].

4. Indigenous Rights and Sovereignty: Indigenous peoples' rights to control and benefit from their genetic resources and traditional knowledge are protected under international agreements such as the United Nations Declaration on the Rights of Indigenous Peoples (UNDRIP) and the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization[16]. These agreements recognize indigenous peoples' rights to free, prior, and informed consent (FPIC) and equitable benefit-sharing in research involving their genetic resources and traditional knowledge.

5. Research Ethics Guidelines: Ethical guidelines and standards established by regulatory bodies, professional associations, and research institutions govern the conduct of research involving human participants, including pharmacogenomics research in traditional

medicine[21]. These guidelines outline principles of research integrity, informed consent, risk-benefit assessment, confidentiality, and community engagement that researchers must adhere to in their research activities[81].

C. Social Implications of Integrating Pharmacogenomics into Traditional Medicine Practices

The integration of pharmacogenomics into traditional medicine practices carries various social implications that can impact individuals, communities, and healthcare systems. Some key social implications include:

1. Cultural Preservation and Revitalization: Pharmacogenomics research involving traditional medicine has the potential to revitalize and preserve indigenous knowledge systems, cultural practices, and healing traditions. By validating the efficacy and safety of traditional remedies through scientific research, pharmacogenomics can contribute to the preservation of cultural heritage and promote cultural pride and identity[82].

2. Health Equity and Access to Care: Integrating pharmacogenomicsinto traditional medicine practices can improve health equity and access to personalized healthcare, particularly for underserved and marginalized populations. By tailoring treatments to individuals' genetic profiles, traditional medicine practitioners can optimize therapeutic outcomes and minimize the risk of adverse reactions, leading to better health outcomes for diverse populations[14].

3. Interdisciplinary Collaboration: Pharmacogenomics research in traditional medicine requires interdisciplinary collaboration between scientists, healthcare providers, traditional healers, community leaders, and policymakers. By bringing together diverse perspectives and expertise, pharmacogenomics research can foster mutual respect, understanding, and collaboration between different knowledge systems and promote holistic approaches to healthcare[83].

4. Education and Awareness: Integrating pharmacogenomics into traditional medicine practices requires education and awareness-building efforts to ensure that healthcare providers, researchers, and communities have the knowledge and skills to understand and utilize genetic information responsibly. Public engagement initiatives, cultural sensitivity training, and capacity-building programs can help bridge the gap between traditional and modern healthcare practices and promote informed decision-making[55].

5. Ethical and Legal Challenges: The integration of pharmacogenomics into traditional medicine practices raises ethical and legal challenges related to informed consent, privacy, data ownership, benefit-sharing, and intellectual property rights. Addressing these challenges requires the development of ethical guidelines, legal frameworks, and governance mechanisms that protect individuals' rights and promote equitable access to personalized healthcare[84].

D. Strategies for Addressing ELSI Concerns and Promoting Equitable Access to Personalized Traditional Medicine

Addressing the ethical, legal, and social implications (ELSI) of integrating pharmacogenomics into traditional medicine requires the development and implementation of comprehensive strategies that promote responsible research conduct, protect individuals' rights, and ensure equitable access to personalized healthcare[36]. Some key strategies include:

1. Community Engagement and Empowerment: Engage with indigenous and local communities in a culturally sensitive and inclusive manner, involving community members in all stages of research planning, implementation, and decision-making. Empower communities to control and benefit from research involving their genetic resources and traditional knowledge, fostering collaboration, trust, and mutual respect[28].

2. Capacity-Building and Education: Provide education and training programs to healthcare providers, researchers, policymakers, and community leaders on the ethical, legal, and social implications of pharmacogenomics in traditional medicine. Build capacity in genetics literacy, cultural competency, and research ethics to ensure that stakeholders have the knowledge and skills to navigate complex ELSI issues responsibly[85].

3. Ethical Guidelines and Governance Mechanisms: Develop and implement ethical guidelines, legal frameworks, and governance mechanisms that address the unique ELSI considerations associated with pharmacogenomics research in traditional medicine. Establish clear policies and procedures for informed consent, privacy protection, benefit-sharing, intellectual property rights, and community engagement, ensuring that research activities are conducted ethically and transparently[86].

4. Equitable Access and Benefit-Sharing: Ensure equitable access to the benefits of pharmacogenomics research and personalized medicine by promoting fair and transparent benefit-sharing arrangements that recognize and compensate indigenous and local communities for their contributions. Implement policies and mechanisms for sharing research data, resources, and technologies in a manner that maximizes benefits for all stakeholders and promotes social justice[87].

5. Advocacy and Policy Reform: Advocate for policy reforms and legislative changes that support the integration of pharmacogenomics into traditional medicine practices while safeguarding individuals' rights and promoting cultural diversity, equity, and inclusion. Collaborate with policymakers, regulatory authorities, and civil society organizations to develop evidence-based policies that address ELSI concerns and promote responsible research conduct[88].

Conclusion

The integration of pharmacogenomics into traditional medicine marks a transformative step forward in healthcare, offering a pathway towards personalized treatment while respecting

cultural diversity and promoting social equity. This integration necessitates a multi-faceted approach that encompasses interdisciplinary collaboration, adherence to rigorous ethical standards, and active engagement with communities. By fostering partnerships between researchers, healthcare providers, policymakers, and indigenous leaders, we can navigate the intricate web of ethical, legal, and social implications (ELSI) inherent in pharmacogenomics research. Through transparent dialogue and inclusive decision-making processes, we can ensure that the benefits of pharmacogenomics are equitably distributed across diverse populations. Moreover, by embracing a holistic perspective that melds scientific innovation with cultural sensitivity and ethical integrity, we can harness the full potential of pharmacogenomics to improve health outcomes, preserve traditional healing practices, and advance global health equity.Moving forward, concerted efforts are needed to address the multifaceted challenges posed by the integration of pharmacogenomics into traditional medicine. This includes enhancing education and awareness among stakeholders to promote a nuanced understanding of the ELSI considerations at play. Additionally, advocacy for policy reforms and legislative changes will be crucial in establishing frameworks that support responsible research conduct while safeguarding individual rights and cultural heritage. Moreover, investment in capacity-building initiatives and infrastructure development is essential to empower communities to actively participate in pharmacogenomics research and benefit from its outcomes. By fostering a collaborative ecosystem that prioritizes transparency, inclusivity, and respect for diverse perspectives, we can navigate the complexities of integrating pharmacogenomics into traditional medicine and realize its potential to revolutionize healthcare delivery.Moreover, efforts to address health disparities and promote social justice must remain central to our endeavors, ensuring that personalized healthcare interventions reach those most in need. By embracing a shared vision of healthcare that values inclusivity, equity, and cultural sensitivity, we can chart a course towards a future where pharmacogenomics empowers individuals, strengthens communities, and transforms lives.

Referencing

[1] Van Der Wouden, C.H., Bohringer, S., Cecchin, E., Cheung, K.-C., Davila-Fajardo, C.L., Deneer, V.H.M., Dolzan, V., Ingelman-Sundberg, M., Jonsson, S., Karlsson, O., et al. "Generating evidence for precision medicine: Considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study." Pharmacogenet. Genom., 2020. DOI: 10.1097/FPC.0000000000000405.

[2] Relling, M.V., Klein, T.E., Gammal, R.S., Whirl-Carrillo, M., Hoffman, J.M., Caudle, K.E. "The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later." Clin. Pharmacol. Ther., 2019, 107, pp. 171–175. DOI: 10.1002/cpt.1651.

[3] Chenoweth, M.J., Giacomini, K.M., Pirmohamed, M., Hill, S.L., Van Schaik, R.H.N., Schwab, M., Shuldiner, A.R., Relling, M.V., Tyndale, R.F. "Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities." Clin. Pharmacol. Ther., 2019, 107, pp. 57–61. DOI: 10.1002/cpt.1664.

[4] Dugo, M., Devecchi, A., De Cecco, L., Cecchin, E., Mezzanzanica, D., Sensi, M., Bagnoli, M. "Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study." Genes., 2019, 10, 678. DOI: 10.3390/genes10090678.

[5] Zazuli, Z., Otten, L.S., Drogemoller, B., Medeiros, M., Monzon, J.G., Wright, G.E.B., Kollmannsberger, C.K., Bedard, P.L., Chen, Z., Gelmon, K.A., et al. "Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients." Genes., 2019, 10, 364. DOI: 10.3390/genes10050364.

[6] Xu, Y., Lin, S., Zhao, H., Wang, J., Zhang, C., Dong, Q., Hu, C., Desi, S., Wang, L., Xu, Y. "Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision drugs for Breast Cancer Patients." Genes., 2019, 10, 657. DOI: 10.3390/genes10090657.

[7] Al-Eitan, L.N., Almasri, A.Y., Khasawneh, R.H. "Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy." Genes., 2018, 9, 578. DOI: 10.3390/genes9120578.

[8] Lucafo, M., Stocco, G., Martelossi, S., Favretto, D., Franca, R., Malusa, N., Lora, A., Bramuzzo, M., Naviglio, S., Cecchin, E., et al. "Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants." Genes., 2019, 10, 277. DOI: 10.3390/genes10040277.

[9] Bhise, N.S., Elsayed, A.H., Cao, X., Pounds, S., Lamba, J.K. "MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia." Genes., 2019, 10, 319. DOI: 10.3390/genes10040319.

[10] Lunenburg, C., Henricks, L.M., Van Kuilenburg, A.B.P., Mathijssen, R.H.J., Schellens, J.H.M., Gelderblom, H., Guchelaar, H.-J., Swen, J.J. "Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants." Genes., 2018, 9, 585. DOI: 10.3390/genes9120585.

[11] Roncato, R., Cin, L.D., Mezzalira, S., Comello, F., De Mattia, E., Bignucolo, A., Giollo, L., D'Errico, S., Gulotta, A., Emili, L., et al. "FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy." Genes., 2019, 10, 276. DOI: 10.3390/genes10040276.

[12] Van Der Wouden, C.H., Bank, P.C.D., Ozokcu, K., Swen, J.J., Guchelaar, H.-J. "Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical

Decision Support in Primary Care: Record of PGx Results and Real-World Impact." Genes., 2019, 10, 416. DOI: 10.3390/genes10060416.

[13] Dávila-Fajardo, C.L., Díaz-Villamarín, X., Antúnez-Rodríguez, A., Fernández-Gómez, A.E., García-Navas, P., Martinez-Gonzalez, L., Dávila-Fajardo, J.A., Barrera, J.C. "Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine." Genes., 2019, 10, 261. DOI: 10.3390/genes10040261.

[14] Pavlovic, S., Kotur, N., Stankovic, B., Zukic, B., Gasic, V., Dokmanovic, L. "Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment." Genes., 2019, 10, 191. DOI: 10.3390/genes10030191.

[15] Pirmohamed, M., "Pharmacogenetics and pharmacogenomics," Br. J. Clin. Pharmacol., vol. 52, pp. 345–347, 2001.

[16] Spear, B. B., Heath-Chiozzi, M., & Huff, J., "Clinical application of pharmacogenetics," Trends Mol. Med., vol. 7, pp. 201–204, 2001.

[17] Connor, S., "Glaxo chief: Our drugs do not work on most patients," Independent (Lond.), Dec. 8, 2003. [Online]. Available: https://www.independent.co.uk/news/science/glaxo-chief-our-drugs-do-not-work-on-most-patients-5508670.html.

[18] Schork, N. J., "Personalized medicine: time for one-person trials," Nature, vol. 520, pp. 609–611, 2015.

[19] Michel, M. C., & Staskin, D., "Study designs for evaluation of combination treatment: focus on individual patient benefit," Biomedicines, vol. 10, p. 270, 2022.

[20] Snapinn, S. M., & Jiang, Q., "Responder analyses and the assessment of a clinically relevant treatment effect," Trials, vol. 8, p. 31, 2007.

[21] Senn, S., "Individual response to treatment: is it a valid assumption?" BMJ, vol. 329, pp. 966–968, 2004.

[22] Lonergan, M., et al., "Defining drug response for stratified medicine," Drug Discov. Today, vol. 22, pp. 173–179, 2017.

[23] Pirmohamed, M., et al., "Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients," BMJ, vol. 329, pp. 15–19, 2004.

[24] Osanlou, R., Walker, L., Hughes, D. A., Burnside, G., & Pirmohamed, M., "Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of

1 month of medical admissions," BMJ Open, vol. 12, p. e055551, 2022.

[25] Davies, E. C., et al., "Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes," PLoS ONE, vol. 4, p. e4439, 2009.

[26] Alhawassi, T. M., Krass, I., Bajorek, B. V., & Pont, L. G., "A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting," Clin. Interv. Aging, vol. 9, pp. 2079–2086, 2014.

[27] Soiza, R. L., "Global pandemic — the true incidence of adverse drug reactions," Age Ageing, vol. 49, pp. 934–935, 2020.

[28] Mostafa, S., Kirkpatrick, C. M. J., Byron, K., & Sheffield, L., "An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes," J. Neural Transm., vol. 126, pp. 5–18, 2019.

[29] Cohn, I., et al., "Genome sequencing as a platform for pharmacogenetic genotyping: a pediatric cohort study," NPJ Genom. Med., vol. 2, p. 19, 2017.

[30] Reisberg, S., et al., "Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions," Genet. Med., vol. 21, pp. 1345–1354, 2019.

[31] Alshabeeb, M. A., Deneer, V. H. M., Khan, A., & Asselbergs, F. W., "Use of pharmacogenetic drugs by the Dutch population," Front. Genet., vol. 10, p. 567, 2019.

[32] Jithesh, P. V., et al., "A population study of clinically actionable genetic variation affecting drug response from the Middle East," NPJ Genom. Med., vol. 7, p. 10, 2022.

[33] McInnes, G., et al., "Pharmacogenetics at scale: an analysis of the UK Biobank," Clin. Pharmacol. Ther., vol. 109, pp. 1528–1537, 2021.

[34] Turner, R. M., de Koning, E. M., Fontana, V., Thompson, A., & Pirmohamed, M., "Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study," BMC Med., vol. 18, p. 367, 2020.

[35] P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," Pharma Science Monitor, vol. 9, no. 2, 2018.

[36] P. Bhatt et al., "Development and characterization of fast dissolving buccal

strip of frovatriptan succinate monohydrate for buccal delivery," Int J Pharm Investig, vol. 11, no. 1, pp. 69–75, 2021.

[37] P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," The Chinese Journal of Artificial Intelligence, 2023.

[38] P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in Blockchain for Healthcare Systems, 2021, pp. 97–113.

[39] P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium–A Review," World J. Pharm. Pharm. Sci, vol. 7, no. 9, pp. 271-287, 2018.

[40] Van Driest, S. L., et al., "Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing," Clin. Pharmacol. Ther., vol. 95, pp. 423–431, 2014.

[41] Ji, Y., et al., "Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade," J. Mol. Diagn., vol. 18, pp. 438–445, 2016.

[42] Dunnenberger, H. M., et al., "Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers," Annu. Rev. Pharmacol. Toxicol., vol. 55, pp. 89–106, 2015.

[43] Kimpton, J. E., et al., "Longitudinal exposure of English primary care patients to pharmacogenomic drugs: an analysis to inform design of pre-emptive pharmacogenomic testing," Br. J. Clin. Pharmacol., vol. 85, pp. 2734–2746, 2019.

[44] Holmes, R. D., Tiwari, A. K., & Kennedy, J. L., "Mechanisms of the placebo effect in pain and psychiatric disorders," Pharmacogenomics J., vol. 16, pp. 491–500, 2016.

[45] Jorgensen, A. L., et al., "Adherence and variability in warfarin dose requirements: assessment in a prospective cohort," Pharmacogenomics, vol. 14, pp. 151–163, 2013.

[46] Agache, I., & Akdis, C. A., "Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases," J. Clin. Invest., vol. 129, pp. 1493–1503, 2019.

[47] Brown, L. C., et al., "Pharmacogenomic testing and depressive symptom

remission: a systematic review and meta-analysis of prospective, controlled clinical trials," Clin. Pharmacol. Ther., 2022. [Online]. Available: https://doi.org/10.1002/cpt.2748.

[48] S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in Advances in Flavonoids for Human Health and Prevention of Diseases, 2024, pp. 23-46.

[49] S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in Blockchain for Healthcare Systems, 2021, pp. 61–79.

[50] S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," Journal of Pharmaceutical Negative Results, pp. 1463-1469, 2022.

[51] Pereira, N. L., et al., "Clopidogrel pharmacogenetics," Circ. Cardiovasc. Interv., vol. 12, p. e007811, 2019.

[52] Shuldiner, A. R., et al., "Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy," JAMA, vol. 302, pp. 849–857, 2009.

[53] Beitelshees, A. L., et al., "CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention in diverse clinical settings," J. Am. Heart Assoc., vol. 11, p. e024159, 2022.

[54] Minderhoud, C., et al., "Increased frequency of CYP2C19 loss-of-function alleles in clopidogrel-treated patients with recurrent cerebral ischemia," Br. J. Clin. Pharmacol., vol. 88, pp. 3335–3340, 2022.

[55] Wang, Y., et al., "Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA," N. Engl. J. Med., vol. 385, pp. 2520–2530, 2021.

[56] Nofziger, C., et al., "PharmVar GeneFocus: CYP2D6," Clin. Pharmacol. Ther., vol. 107, pp. 154–170, 2020.

[57] Carranza-Leon, D., et al., "CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice," Pharmacogenomics J., vol. 21, pp. 484–490, 2021.

[58] Koren, G., et al., "Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother," Lancet, vol. 368, p. 704, 2006.

[59] S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.

[60] V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," International Journal of Pharmaceutical Sciences and Research, vol. 11, no. 5, pp. 2193–2198, 2020.

[61] A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," GSC biol pharm sci, vol. 19, no. 3, pp. 148–155, 2022.

[62] B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., Encyclopedia of green materials. Singapore: Springer Nature Singapore, 2022.

[63] P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy- A review," Am J PharmTech Res, vol. 9, no. 3, pp. 321–331, 2019.

[64] P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in The Flavonoids, 2024, pp. 131-152.

[65] P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch," ACS Omega, vol. 8, no. 33, pp. 30294–305, 2023.

[66] P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," Pharmaceutics, vol. 15, no. 8, p. 2066, 2023.

[67] C. Goyal et al., "Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents," Res J Pharm Technol, pp. 5078–5083, 2022.

[68] T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," J Pharm Res Int, pp. 70–78, 2021.

[69] M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," Phytomed Plus, vol. 3, no. 2, p. 100445, 2023.

[70] A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," J Chem Pharm Sci, vol. 12, no. 03, pp. 71–78, 2019.

[71] M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," Nat Prod J, 2022.

[72] M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino

mice," ACS Omega, vol. 7, no. 40, pp. 35506–35514, 2022.

[73] M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," ACS Omega, vol. 8, no. 13, pp. 11750–11767, 2023.

[74] Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," J Pharm Res Int, pp. 54–63, 2021.

[75] Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," J Pharm Res Int, pp. 21–29, 2021.

[76] V. Raghuwanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," Journal of Pharmaceutical Negative Results, pp. 1811-1820, 2022.

[77] K. K. Sahu et al., "Utility of nanomaterials in wound management," in Nanotechnological Aspects for Next-Generation Wound Management, 2024, pp. 101–130.

[78] S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," J Infect Public Health, vol. 15, no. 5, pp. 566–572, 2022.

[79] S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," J Pharm Res Int, pp. 5–13, 2021.

[80] S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," Journal of Pharmaceutical Research International, vol. 32, no. 36, pp. 82-88, 2022.

[81] S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," WJPMR, vol. 8, no. 4, pp. 216–225, 2022.

[82] R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in 2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART), 2023, pp. 556-561.

[83] P. Bhatt et al., “Impact of cross-linking on the physicochemical and physiological characteristics of barnyard millet (Echinochloa frumentacea) grains starch,” Starke, 2024.

[84] Kelly, L. E., et al., "More codeine fatalities after tonsillectomy in North American children," Pediatrics, vol. 129, pp. e1343–e1347, 2012.

[85] Volpi, S., et al., "Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects," Clin. Pharmacol. Ther., vol. 103, pp. 778–786, 2018.

[86] Magavern, E. F., et al., "Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy," Eur. Heart J. Cardiovasc. Pharmacother., vol. 8, pp. 100–103, 2022.

[87] Pirmohamed, M., & Hughes, D. A., "Pharmacogenetic tests: the need for a level playing field," Nat. Rev. Drug Discov., vol. 12, pp. 3–4, 2013.

[88] Concato, J., "Observational versus experimental studies: what’s the evidence for a hierarchy?" NeuroRx, vol. 1, pp. 341–347, 2004.